Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Egerer

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Blood|November 11, 2006
Circulating proteasome levels are an independent prognostic factor for survival in multiple myelomaChristian Jakob, Karl Egerer, Peter Liebisch, et al.
Arthritis Research & Therapy|February 18, 2009
Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patientsKatharina Hanke, Claudia S Brückner, Cornelia Dähnrich, et al.
The Journal of Rheumatology|March 19, 2013
Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndromeLorena Martinez-Gamboa, Karsten Lesemann, Ulrike Kuckelkorn, et al.
Annals of the Rheumatic Diseases|June 29, 2012
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated studyJacqueline Detert, Hans Bastian, Joachim Listing, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Blood|November 11, 2006
Circulating proteasome levels are an independent prognostic factor for survival in multiple myelomaChristian Jakob, Karl Egerer, Peter Liebisch, et al.
Arthritis Research & Therapy|February 18, 2009
Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patientsKatharina Hanke, Claudia S Brückner, Cornelia Dähnrich, et al.
The Journal of Rheumatology|March 19, 2013
Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndromeLorena Martinez-Gamboa, Karsten Lesemann, Ulrike Kuckelkorn, et al.
Annals of the Rheumatic Diseases|June 29, 2012
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated studyJacqueline Detert, Hans Bastian, Joachim Listing, et al.
Pageof 4